These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 35337110)
41. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC; Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456 [TBL] [Abstract][Full Text] [Related]
42. Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes? Ahmad E; Sargeant JA; Zaccardi F; Khunti K; Webb DR; Davies MJ Pharmaceuticals (Basel); 2020 Nov; 13(12):. PubMed ID: 33261058 [TBL] [Abstract][Full Text] [Related]
43. Metformin for diabetes prevention: update of the evidence base. Hostalek U; Campbell I Curr Med Res Opin; 2021 Oct; 37(10):1705-1717. PubMed ID: 34281467 [TBL] [Abstract][Full Text] [Related]
44. Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research. Li JZ; Li YR Cardiology; 2023; 148(4):374-384. PubMed ID: 37307806 [TBL] [Abstract][Full Text] [Related]
45. The pleiotropic effects of metformin: time for prospective studies. Bromage DI; Yellon DM Cardiovasc Diabetol; 2015 Aug; 14():109. PubMed ID: 26271457 [TBL] [Abstract][Full Text] [Related]
46. Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. Lund A; Knop FK Curr Med Res Opin; 2012 May; 28(5):731-6. PubMed ID: 22462528 [TBL] [Abstract][Full Text] [Related]
47. Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. Tong X; Xu J; Lian F; Yu X; Zhao Y; Xu L; Zhang M; Zhao X; Shen J; Wu S; Pang X; Tian J; Zhang C; Zhou Q; Wang L; Pang B; Chen F; Peng Z; Wang J; Zhen Z; Fang C; Li M; Chen L; Zhao L mBio; 2018 May; 9(3):. PubMed ID: 29789365 [TBL] [Abstract][Full Text] [Related]
48. Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin. Chan JCN; Yang A; Chu N; Chow E Diabetes Obes Metab; 2024 Aug; 26 Suppl 3():55-74. PubMed ID: 38992869 [TBL] [Abstract][Full Text] [Related]
49. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610 [TBL] [Abstract][Full Text] [Related]
50. Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis. Zhang K; Yang W; Dai H; Deng Z Diabetes Res Clin Pract; 2020 Feb; 160():108001. PubMed ID: 31904444 [TBL] [Abstract][Full Text] [Related]
52. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile. Scheen AJ Expert Opin Drug Saf; 2024 Jul; 23(7):797-810. PubMed ID: 38738549 [TBL] [Abstract][Full Text] [Related]
53. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. Thrasher J Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343 [TBL] [Abstract][Full Text] [Related]
54. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus. Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326 [TBL] [Abstract][Full Text] [Related]
55. Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. Cai H; Chen Q; Duan Y; Zhao Y; Zhang X Front Endocrinol (Lausanne); 2023; 14():1106868. PubMed ID: 36777344 [TBL] [Abstract][Full Text] [Related]
56. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition. Dokken B J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138 [TBL] [Abstract][Full Text] [Related]
57. Effect of metformin on adverse outcomes in T2DM patients: Systemic review and meta-analysis of observational studies. Xu Z; Zhang H; Wu C; Zheng Y; Jiang J Front Cardiovasc Med; 2022; 9():944902. PubMed ID: 36211585 [TBL] [Abstract][Full Text] [Related]
58. An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis. Markowicz-Piasecka M; Sadkowska A; Huttunen KM; Podsiedlik M; Mikiciuk-Olasik E; Sikora J Eur J Pharmacol; 2020 Apr; 872():172984. PubMed ID: 32017937 [TBL] [Abstract][Full Text] [Related]
59. Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials. Peng Y; Chen SH; Liu XN; Sun QY J Cell Physiol; 2019 Mar; 234(3):2795-2806. PubMed ID: 30145806 [TBL] [Abstract][Full Text] [Related]
60. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin. Chamarthi B; Ezrokhi M; Rutty D; Cincotta AH Postgrad Med; 2016 Nov; 128(8):761-769. PubMed ID: 27687032 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]